Feb 29, 2024
BioCryst Pharmaceuticals Inc. Achieves Impressive Double-Digit Top-Line Growth in Fourth Quarter of 2023 https://csimarket.com/stocks/news.php?code=BCRX&date=2024-02-28145615&utm_source=dlvr.it&utm_medium=tumblr
seen from Germany
seen from United States
seen from United States
seen from Türkiye
seen from Brazil
seen from Singapore
seen from Germany
seen from Spain
seen from Tunisia
seen from Malaysia
seen from Germany
seen from China
seen from China
seen from Germany
seen from Malaysia
seen from China
seen from Guatemala
seen from Chile
seen from United States
seen from Malaysia
BioCryst Pharmaceuticals Inc. Achieves Impressive Double-Digit Top-Line Growth in Fourth Quarter of 2023 https://csimarket.com/stocks/news.php?code=BCRX&date=2024-02-28145615&utm_source=dlvr.it&utm_medium=tumblr
And my journey into stocks is now going to take the next step. Let’s fucking go!
BioCryst Pharmaceuticals (BCRX) Q4 2019 Earnings Snapshot
BioCryst Pharmaceuticals (BCRX) Q4 2019 Earnings Snapshot
— BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of $0.26 per share.
— Revenue was $39.7 million vs. $2.7 million in the fourth quarter of 2018 and targeted revenue of $9.88 million.
— R&D expenses increased to $26.8 million from $23.4 million in the prior-year quarter.
— For full-year 2020, operating cash use…
View On WordPress
Apellis Pharmaceuticals (APLS:NAS) Fundamental Valuation Report
Apellis Pharmaceuticals (APLS:NAS) Fundamental Valuation Report
Fundamental Valuation Report
Apellis Pharmaceuticals(APLS:NAS) Healthcare:Biotechnology
This Report was…
View On WordPress
Alder BioPharmaceuticals (ALDR:NAS) Fundamental Valuation Report
Alder BioPharmaceuticals (ALDR:NAS) Fundamental Valuation Report
Fundamental Valuation Report
Alder BioPharmaceuticals(ALDR:NAS) Healthcare:Biotechnology
This Report was…
View On WordPress
BioCryst Has An Expected Turning Point In 2019 That Could Shift Momentum
BioCryst Has An Expected Turning Point In 2019 That Could Shift Momentum
BioCryst Pharmaceuticals (BCRX) is expected to release results from its prophylactic treatment for patients with Hereditary Angioedema (HAE). Specifically, in Q2 of 2019, it expects to release results from its phase 3 APeX-2 study. These results will be very important, because it involves a late-stage study that could potentially be used for approval of BCX7353.
BCX7353 As A Prophylaxis
BioCryst…
View On WordPress
Trading At Over Twice The 52 Week Low, BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) Close At $9.31
Trading At Over Twice The 52 Week Low, BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) Close At $9.31
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX)
November 26th, 2018 With markets going up BioCryst Pharmaceuticals, Inc. finished Monday’s trading session down 0.43%, a $0.04 decrease to close on $9.31. While the stock did drop today, remember that it is still trading at 119% of its 52 week low of $4.25. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is…
View On WordPress
(Nasdaq:BCRX) BioCryst Pharmaceuticals, Inc. Breaks 52 Week High Record
(Nasdaq:BCRX) BioCryst Pharmaceuticals, Inc. Breaks 52 Week High Record
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX)
November 8th, 2018 BioCryst Pharmaceuticals, Inc. closed the day up $0.10 Thursday which equals a 1.25% jump, closing at $8.09. Furthermore it hit a new 52 week high of $8.31. BioCryst Pharmaceuticals, Inc. swung 7.23% between high and low. Be aware that the Altman Z-Score1 (An indicator of the probability for a 2-year bankruptcy) is below the…
View On WordPress